A patient with transthyretin amyloidosis (ATTR) who received the investigational gene therapy nexiguran ziclumeran (nex-z) in ...

Disrupted sleep patterns in Alzheimer’s disease may be more than a symptom—they could be a driving force. Researchers at ...

Intellia Therapeutics (NTLA) stock plummets after the company's Q3 updates indicate a patient deeath in a Phase 3 for its nex ...

Alzheimer’s disease not only damages memory but also distorts the brain’s internal clock, disrupting the daily rhythms of hundreds of genes tied to brain health.

Lowering the transcription factor PU.1 reprograms microglia into a neuroprotective, lymphoid-like state that compacts amyloid ...

In a first for adults in Singapore, scientists are conducting gene editing trials on heart patients to correct defects at ...

Intellia Therapeutics has acknowledged the death of the elderly patient hospitalized last week in its Phase III trial of assessing nexiguran ziclumeran (nex-z) in transthyretin amyloidosis with ...

The experimental pill ALZ-801 slowed memory decline by 50% and reduced brain shrinkage in early Alzheimer's patients with ...

The FDA previously placed two clinical studies on hold, including the Phase III trial in which the liver toxicity occurred.

New diagnostic kits aim to revolutionize early screening of the disease, potentially allowing patients to receive ...

The patient who was hospitalized after receiving Intellia Therapeutics’ CRISPR therapy nex-z has died. | The patient who was ...